PCORI Board Approves $142.5 Million to Fund Expansion Phase of PCORnet, the National Patient-Centered Clinical Research Network

WASHINGTON, DC (July 21, 2015) – The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved nearly $142.5 million to support the ongoing development and expansion of an ambitious new resource for health research known as PCORnet, the National Patient-Centered Clinical Research Network.

Read more…

Loading

A media-savvy caregiver brings Alzheimer’s patients to the table in drug research

Meryl Comer sat on stage at the BIO International Convention in San Diego last month between two prominent scientists: Francis S. Collins, director of the National Institutes of Health, and Jan M. Lundberg, head of R&D at Eli Lilly & Co. The three were on hand to discuss the Accelerating Medicines Partnership, or AMP, a new public-private drug discovery consortium. A former television news reporter who now heads the Geoffrey Beene Foundation Alzheimer’s Initiative, Comer leveraged her mastery of visual communication to solidly upstage her copanelists.

Read full article.

Loading

Deaths from Alzheimer’s more than reported, study says

Alzheimer’s disease accounts for many more deaths than we’ve realized, a new study concludes, making it nearly as lethal as the nation’s two biggest killers, heart disease and cancer.

Death certificates record immediate cause of death, but often miss the underlying cause, which is why Alzheimer’s has been undercounted, according to Bryan James, an epidemiologist at Rush University Medical Center in Chicago, who led the research.

Read full article.

Loading

AMPlifying targets

C. Simone FIshburn, February 27, 2014, SciBX – Science-Business eXchange

Although small- and medium-sized biotechs are absent from the NIH’s new Accelerated Medicines Partnership with industry and not-for-profit organizations, consortium leaders expect that making results publicly available on their search for new targets and biomarkers in four diseases will benefit all players. However, it is unclear whether the $230 million, 5-year fund is adequately financed to meet the partnership’s goal of accelerating target discovery.

Read full article.

Loading